Validation and Utility of a Non-Invasive 2-Gene Molecular Assay for Cutaneous Melanoma

Laura K. Ferris, MD, PhD¹, Burkhard Jansen, MD², Jonathan Ho, MD³, Klaus J. Busam, MD⁴, Kenneth Goss, MD⁵, Doyle D. Hansen, MD⁶, John P. Alsobrook II, PhD⁷, Zuxu Yao, PhD⁸, and Pedram Gerami, MD⁹

**Background:** To minimize the number of melanomas missed, clinicians generally biopsy 10 or more benign nevi for each melanoma. This low specificity results in many unnecessary procedures for patients.

**Approach:** We have previously reported on a pigmented lesion assay (PLA) concept where samples are obtained non-invasively via adhesive patch sampling. We here evaluated the performance of a novel and optimized gene signature using two genes, *LINC* and *PRAME*, to distinguish benign nevi from melanoma in prospectively collected samples (n=319). In addition, using a web based multi-reader multi-case study, 45 dermatologists each evaluated 60 representative clinical and dermatoscopic images of clinically atypical pigmented lesions from the validation study, first without and then with PLA data.

**Results:** The PLA is a sensitive and specific method for detection of cutaneous melanoma (AUC 0.91, NPV>99%, sensitivity 92%, specificity 64%). Dermatologists who incorporated the PLA into their biopsy decision improved their relative biopsy specificity by 77.3% (p<0.001), and improved biopsy sensitivity from 95.0% to 98.6% (p=0.01), compared to their decision without the PLA.

**Innovation and Relevance:** The PLA is a non-invasive tool that enables dermatologists to significantly improve biopsy specificity, thus removing fewer benign nevi, while maintaining or improving sensitivity.
Presenting Author:
Laura Ferris, MD, PhD
Department of Dermatology, University of Pittsburgh
3601 Fifth Avenue, Fifth Floor, Pittsburgh, PA 15238
Phone: 412-647-2013
Email: ferrislk@upmc.edu

About DermTech:
DermTech is a molecular diagnostics company focused on developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA laboratory located at the company’s La Jolla, CA headquarters. DermTech’s technology allows the analysis of skin samples biopsied non-invasively using an adhesive patch rather than a scalpel. DermTech provides highly accurate, objective information to the physicians to improve patient care through advanced molecular pathology gene expression information.